TherapeuticsMD, Inc. business relationships
Companies named in TherapeuticsMD, Inc.’s 10-K filed 2026-03-30, and public companies whose annual reports name TherapeuticsMD, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 46 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in TherapeuticsMD, Inc.’s annual report 3
“into long-term supply agreements with Catalent Pharma Solutions, LLC for the commercial supply of IMVEXXY and BIJUVA which have been” SEC filing
“| Amendment No. 1 to the License Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December 30, 2022 (14) |” SEC filing
“agreement (the "Knight License Agreement") with Knight Therapeutics Inc. ("Knight") pursuant to which we” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.